$0.28
-0.07 (-20.88%)
Open$0.35
Previous Close$0.35
Day High$0.36
Day Low$0.28
52W High$3.05
52W Low$0.25
Volume—
Avg Volume1.91M
Market Cap20.06M
P/E Ratio—
EPS$-2.04
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,556.2% upside
Current
$0.28
$0.28
Target
$7.44
$7.44
$4.65
$7.44 avg
$8.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.30M | 4.98M | 4.38M |
| Net Income | -11,481 | -9,902 | -8,948 |
| Profit Margin | -0.2% | -0.2% | -0.2% |
| EBITDA | -10,930 | -11,209 | -8,630 |
| Free Cash Flow | -9,428 | -11,072 | -6,340 |
| Rev Growth | +3.9% | +11.7% | +7.6% |
| Debt/Equity | 0.42 | 0.41 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |